Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214529002> ?p ?o ?g. }
- W4214529002 endingPage "73" @default.
- W4214529002 startingPage "52" @default.
- W4214529002 abstract "Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that compromises their immune response to infections and vaccines. For this reason, SOT patients have a high risk of developing severe coronavirus disease 2019 (COVID-19) and an increased risk of death from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Moreover, the efficiency of immunotherapies and vaccines is reduced due to the constant immunosuppression in this patient group. Here, we propose adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, tacrolimus, for optimized performance in the immunosuppressed patient. Using a ribonucleoprotein approach of CRISPR-Cas9 technology, we have generated tacrolimus-resistant SARS-CoV-2-specific T cell products from convalescent donors and demonstrate their specificity and function through characterizations at the single-cell level, including flow cytometry, single-cell RNA (scRNA) Cellular Indexing of Transcriptomes and Epitopes (CITE), and T cell receptor (TCR) sequencing analyses. Based on the promising results, we aim for clinical validation of this approach in transplant recipients. Additionally, we propose a combinatory approach with tacrolimus, to prevent an overshooting immune response manifested as bystander T cell activation in the setting of severe COVID-19 immunopathology, and tacrolimus-resistant SARS-CoV-2-specific T cell products, allowing for efficient clearance of viral infection. Our strategy has the potential to prevent severe COVID-19 courses in SOT or autoimmunity settings and to prevent immunopathology while providing viral clearance in severe non-transplant COVID-19 cases." @default.
- W4214529002 created "2022-03-02" @default.
- W4214529002 creator A5002084661 @default.
- W4214529002 creator A5009014320 @default.
- W4214529002 creator A5023491296 @default.
- W4214529002 creator A5027416201 @default.
- W4214529002 creator A5030126089 @default.
- W4214529002 creator A5030529606 @default.
- W4214529002 creator A5033374084 @default.
- W4214529002 creator A5037283048 @default.
- W4214529002 creator A5038032799 @default.
- W4214529002 creator A5043677331 @default.
- W4214529002 creator A5047806143 @default.
- W4214529002 creator A5049060150 @default.
- W4214529002 creator A5052861657 @default.
- W4214529002 creator A5060966829 @default.
- W4214529002 creator A5061694042 @default.
- W4214529002 creator A5063466900 @default.
- W4214529002 creator A5072736639 @default.
- W4214529002 creator A5080260380 @default.
- W4214529002 creator A5089271779 @default.
- W4214529002 creator A5091738640 @default.
- W4214529002 date "2022-06-01" @default.
- W4214529002 modified "2023-10-18" @default.
- W4214529002 title "Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients" @default.
- W4214529002 cites W1761637772 @default.
- W4214529002 cites W1910012553 @default.
- W4214529002 cites W196757896 @default.
- W4214529002 cites W1973871916 @default.
- W4214529002 cites W1973876618 @default.
- W4214529002 cites W1987058037 @default.
- W4214529002 cites W1993512576 @default.
- W4214529002 cites W1993728343 @default.
- W4214529002 cites W2004709238 @default.
- W4214529002 cites W2014795514 @default.
- W4214529002 cites W2021936785 @default.
- W4214529002 cites W2023676063 @default.
- W4214529002 cites W2024494089 @default.
- W4214529002 cites W2025080738 @default.
- W4214529002 cites W2034359690 @default.
- W4214529002 cites W2036032415 @default.
- W4214529002 cites W2038621149 @default.
- W4214529002 cites W2043948827 @default.
- W4214529002 cites W2046753941 @default.
- W4214529002 cites W2046775408 @default.
- W4214529002 cites W2051161103 @default.
- W4214529002 cites W2057547483 @default.
- W4214529002 cites W2058192618 @default.
- W4214529002 cites W2060004314 @default.
- W4214529002 cites W2060140838 @default.
- W4214529002 cites W2067468716 @default.
- W4214529002 cites W2071554306 @default.
- W4214529002 cites W2089297905 @default.
- W4214529002 cites W2091038501 @default.
- W4214529002 cites W2092643850 @default.
- W4214529002 cites W2107777135 @default.
- W4214529002 cites W2123887660 @default.
- W4214529002 cites W2124573333 @default.
- W4214529002 cites W2133516504 @default.
- W4214529002 cites W2142210684 @default.
- W4214529002 cites W2142285934 @default.
- W4214529002 cites W2144463184 @default.
- W4214529002 cites W2153549003 @default.
- W4214529002 cites W2323691815 @default.
- W4214529002 cites W2329622628 @default.
- W4214529002 cites W2340809593 @default.
- W4214529002 cites W2344961767 @default.
- W4214529002 cites W2516455020 @default.
- W4214529002 cites W2526704351 @default.
- W4214529002 cites W2535622376 @default.
- W4214529002 cites W2540833380 @default.
- W4214529002 cites W2613573069 @default.
- W4214529002 cites W2769689735 @default.
- W4214529002 cites W2774214122 @default.
- W4214529002 cites W2886819502 @default.
- W4214529002 cites W2903754922 @default.
- W4214529002 cites W2918940752 @default.
- W4214529002 cites W2947490464 @default.
- W4214529002 cites W2952815301 @default.
- W4214529002 cites W3002623081 @default.
- W4214529002 cites W3007431900 @default.
- W4214529002 cites W3007940623 @default.
- W4214529002 cites W3008028633 @default.
- W4214529002 cites W3009885589 @default.
- W4214529002 cites W3011117765 @default.
- W4214529002 cites W3011508332 @default.
- W4214529002 cites W3011610993 @default.
- W4214529002 cites W3011976215 @default.
- W4214529002 cites W3012195391 @default.
- W4214529002 cites W3013843138 @default.
- W4214529002 cites W3015225661 @default.
- W4214529002 cites W3015820665 @default.
- W4214529002 cites W3016771389 @default.
- W4214529002 cites W3017734961 @default.
- W4214529002 cites W3018868982 @default.
- W4214529002 cites W3022878099 @default.
- W4214529002 cites W3023264778 @default.
- W4214529002 cites W3023991776 @default.